N-methyl-d-aspartate receptor NR2B subunit involved in depression-like behaviours in lithium chloride-pilocarpine chronic rat epilepsy model

Epilepsy Research

Volumn 119, Issue , 2016, Pages 77-85

  Peng, Wei Feng ^a   Ding, Jing ^a   Li, Xin ^a   Fan, Fan ^a   Zhang, Qian Qian ^a   Wang, Xin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Depression; Epilepsy; Glutamate; N methyl d aspartate receptor; NR2B subunit

Indexed keywords

LITHIUM CHLORIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PILOCARPINE; CELL NUCLEUS ANTIGEN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N-METHYL D-ASPARTATE RECEPTOR SUBTYPE 2A; NERVE PROTEIN; NEUN PROTEIN, RAT; NR1 NMDA RECEPTOR; NR2B NMDA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DENTATE GYRUS; DEPRESSION; DISEASE ASSOCIATION; EPILEPSY; FORCED SWIM TEST; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; IMMOBILITY TIME; IMMUNOFLUORESCENCE; LATENT PERIOD; MALE; MOLECULAR DYNAMICS; NONHUMAN; PARAMETERS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; SEIZURE; SPONTANEOUS RECURRENT SEIZURE; WESTERN BLOTTING; ANIMAL; CHRONIC DISEASE; DISEASE MODEL; HIPPOCAMPUS; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PSYCHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIGENS, NUCLEAR; CHRONIC DISEASE; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; EPILEPSY; HIPPOCAMPUS; LITHIUM CHLORIDE; MALE; NERVE TISSUE PROTEINS; NEURONS; PHOSPHORYLATION; PILOCARPINE; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SEIZURES;

EID: 84955271438     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2015.09.013     Document Type: Article

References (60)

1. Al-Ghoul W.M., Meeker R.B., Greenwood R.S. Amygdala kindling alters N-methyl-d-aspartate receptor subunit messenger RNA expression in the rat supraoptic nucleus. Neuroscience 1997, 77:985-992.
2. Briellmann R.S., Hopwood M.J., Jackson G.D. Major depression in temporal lobe epilepsy with hippocampalsclerosis: clinical and imaging correlates. J. Neurol. Neurosurg. Psychiatry 2007, 78:1226-1230.
3. Carlson H., Ronne-Engstrom E., Ungerstedt U., Hillered L. Seizure related elevations of extracellular amino acids in human focal epilepsy. Neurosci. Lett. 1992, 140:30-32.
4. Castillo M., Kwock L., Courvoisie H., Hooper S.R. Proton MR spectroscopy in children with bipolar affective disorder: preliminary observations. AJNR Am. J. Neuroradiol. 2000, 21:832-838.
5. Cavus I., Kasoff W.S., Cassaday M.P., Jacob R., Gueorguieva R., Sherwin R.S., Krystal J.H., Spencer D.D., Abi-Saab W.M. Extracellular metabolites in the cortex and hippocampus of epileptic patients. Ann. Neurol. 2005, 57:226-235.
6. Cramer J.A., Blum D., Reed M., Fanning K. The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav. 2003, 4:515-521.
7. Curia G., Longo D., Biagini G., Jones R.S., Avoli M. The pilocarpine model of temporal lobe epilepsy. J. Neurosci. Methods 2008, 172:143-157.
8. Danober L., Deransart C., Depaulis A., Vergnes M., Marescaux C. Pathophysiological mechanisms of genetic absence epilepsy in the rat. Prog. Neurobiol. 1998, 55:27-57.
9. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995, 121:66-72.
10. Di Maio R., Mastroberardino P.G., Hu X., Montero L., Greenamyre J.T. Pilocapine alters NMDA receptor expression and function in hippocampal neurons: NADPH oxidase and ERK1/2 mechanisms. Neurobiol. Dis. 2011, 42:482-495.
11. Di Maio R., Mastroberardino P.G., Hu X., Montero L.M., Greenamyre J.T. Thiol oxidation and altered NR2B/NMDA receptor functions in in vitro and in vivo pilocarpine models: implications for epileptogenesis. Neurobiol. Dis. 2012, 49C:87-98.
12. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., Kammerer W.A., Quezado Z., Luckenbaugh D.A., Salvadore G., Machado-Vieira R., Manji H.K., Zarate C.J. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010, 67:793-802.
13. Do N.A., Dos S.N., Campos P.F., Aparecida T.S., de Moraes F.E., Langone F. Neuronal degeneration and gliosis time-course in the mouse hippocampal formation after pilocarpine-induced status epilepticus. Brain Res. 2012, 1470:98-110.
14. During M.J., Spencer D.D. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 1993, 341:1607-1610.
15. Ettinger A., Reed M., Cramer J. Depression and comorbidity in community-based patients with epilepsy or asthma. Neurology 2004, 63:1008-1014.
16. Fiest K.M., Dykeman J., Patten S.B., Wiebe S., Kaplan G.G., Maxwell C.J., Bulloch A.G., Jette N. Depression in epilepsy: a systematic review and meta-analysis. Neurology 2013, 80:590-599.
17. Finegersh A., Avedissian C., Shamim S., Dustin I., Thompson P.M., Theodore W.H. Bilateral hippocampal atrophy in temporal lobe epilepsy: effect of depressive symptoms and febrile seizures. Epilepsia 2011, 52:689-697.
18. Frasca A., Aalbers M., Frigerio F., Fiordaliso F., Salio M., Gobbi M., Cagnotto A., Gardoni F., Battaglia G.S., Hoogland G., Di Luca M., Vezzani A. Misplaced NMDA receptors in epileptogenesis contribute to excitotoxicity. Neurobiol. Dis. 2011, 43:507-515.
19. Gandy M., Sharpe L., Perry K.N. Psychosocial predictors of depression and anxiety in patients with epilepsy: a systematic review. J. Affect. Disord. 2012, 140:222-232.
20. Garcia C.S. Depression in temporal lobe epilepsy: a review of prevalence, clinical features, and management considerations. Epilepsy Res. Treat. 2012, 2012:809843.
21. Garcia L.S., Comim C.M., Valvassori S.S., Reus G.Z., Stertz L., Kapczinski F., Gavioli E.C., Quevedo J. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:450-455.
22. Ghasemi M., Montaser-Kouhsari L., Shafaroodi H., Nezami B.G., Ebrahimi F., Dehpour A.R. NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test. Psychopharmacology (Berl) 2009, 206:325-333.
23. Ghasemi M., Raza M., Dehpour A.R. NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. J. Psychopharmacol. 2010, 24:585-594.
24. Gilliam F.G., Maton B.M., Martin R.C., Sawrie S.M., Faught R.E., Hugg J.W., Viikinsalo M., Kuzniecky R.I. Hippocampal 1H-MRSI correlates with severity of depression symptoms in temporal lobe epilepsy. Neurology 2007, 68:364-368.
25. Harden C.L. The co-morbidity of depression and epilepsy: epidemiology, etiology, and treatment. Neurology 2002, 59:S48-S55.
26. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 2002, 5:405-414.
27. Hrncic D., Rasic-Markovic A., Susic V., Djuric D., Stanojlovic O. Influence of NR2B-selective NMDA antagonist on lindane-induced seizures in rats. Pharmacology 2009, 84:234-239.
28. Huang H.Y., Lee H.W., Chen S.D., Shaw F.Z. Lamotrigine ameliorates seizures and psychiatric comorbidity in a rat model of spontaneous absence epilepsy. Epilepsia 2012, 53:2005-2014.
29. Ibrahim L., Diaz G.N., Jolkovsky L., Brutsche N., Luckenbaugh D.A., Herring W.J., Potter W.Z., Zarate C.J. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J. Clin. Psychopharmacol. 2012, 32:551-557.
30. Jones N.C., Salzberg M.R., Kumar G., Couper A., Morris M.J., O'Brien T.J. Elevated anxiety and depressive-like behavior in a rat model of genetic generalized epilepsy suggesting common causation. Exp. Neurol. 2008, 209:254-260.
31. Kalia L.V., Kalia S.K., Salter M.W. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 2008, 7:742-755.
32. Kanner A.M. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders?. Lancet Neurol. 2012, 11:1093-1102.
33. Kanner A.M. Psychiatric comorbidities and epilepsy: is it the old story of the chicken and the egg?. Ann. Neurol. 2012, 72:153-155.
34. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
35. Li S.T., Ju J.G. Functional roles of synaptic and extrasynaptic NMDA receptors in physiological and pathological neuronal activities. Curr. Drug Targets 2012, 13:207-221.
36. Mathern G.W., Pretorius J.K., Mendoza D., Leite J.P., Chimelli L., Born D.E., Fried I., Assirati J.A., Ojemann G.A., Adelson P.D., Cahan L.D., Kornblum H.I. Hippocampal N-methyl-d-aspartate receptor subunit mRNA levels in temporal lobe epilepsy patients. Ann. Neurol. 1999, 46:343-358.
37. Mathern G.W., Pretorius J.K., Mendoza D., Lozada A., Leite J.P., Chimelli L., Fried I., Sakamoto A.C., Assirati J.A., Adelson P.D. Increased hippocampal AMPA and NMDA receptor subunit immunoreactivity in temporal lobe epilepsy patients. J. Neuropathol. Exp. Neurol. 1998, 57:615-634.
38. Mathew S.J., Shah A., Lapidus K., Clark C., Jarun N., Ostermeyer B., Murrough J.W. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 2012, 26:189-204.
39. Mazarati A., Siddarth P., Baldwin R.A., Shin D., Caplan R., Sankar R. Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 2008, 131:2071-2083.
40. Mazarati A.M., Shin D., Kwon Y.S., Bragin A., Pineda E., Tio D.N., Taylor A., Sankar R. Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy. Neurobiol. Dis. 2009, 34:457-461.
41. Michael N., Erfurth A., Ohrmann P., Arolt V., Heindel W., Pfleiderer B. Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychol. Med. 2003, 33:1277-1284.
42. Mitchell N.D., Baker G.B. An update on the role of glutamate in the pathophysiology of depression. Acta Psychiatr. Scand. 2010, 122:192-210.
43. Moddel G., Jacobson B., Ying Z., Janigro D., Bingaman W., Gonzalez-Martinez J., Kellinghaus C., Prayson R.A., Najm I.M. The NMDA receptor NR2B subunit contributes to epileptogenesis in human cortical dysplasia. Brain Res. 2005, 1046:10-23.
44. Muller C.J., Groticke I., Bankstahl M., Loscher W. Behavioral and cognitive alterations, spontaneous seizures, and neuropathology developing after a pilocarpine-induced status epilepticus in C57BL/6 mice. Exp. Neurol. 2009, 219:284-297.
45. Nadler J.V. Plasticity of glutamate synaptic mechanisms. Jasper's Basic Mechanisms of the Epilepsies 2012, 1-17. Oxford University Press, Oxford, c2012. 4th ed. J.L. Noebels, H.H. Jasper (Eds.).
46. Neppl R., Nguyen C.M., Bowen W., Al-Saadi T., Pallagi J., Morris G., Mueller W., Johnson R., Prost R., Rand S.D. In vivo detection of postictal perturbations of cerebral metabolism by use of proton MR spectroscopy: preliminary results in a canine model of prolonged generalized seizures. AJNR Am. J. Neuroradiol. 2001, 22:1933-1943.
47. Peng W.F., Ding J., Mao L.Y., Li X., Liang L., Chen C.Z., Cheng W.Z., Fan W., Wang X. Increased ratio of glutamate/glutamine to creatine in the right hippocampus contributes to depressive symptoms in patients with epilepsy. Epilepsy Behav. 2013, 29:144-149.
48. Pineda E.A., Hensler J.G., Sankar R., Shin D., Burke T.F., Mazarati A.M. Plasticity of presynaptic and postsynaptic serotonin 1A receptors in an animal model of epilepsy-associated depression. Neuropsychopharmacology 2011, 36:1305-1316.
49. Pittenger C., Sanacora G., Krystal J.H. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol. Disord. Drug Targets 2007, 6:101-115.
50. Porsolt R.D., Bertin A., Blavet N., Deniel M., Jalfre M. Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur. J. Pharmacol. 1979, 57:201-210.
51. Pucilowski O., Overstreet D.H., Rezvani A.H., Janowsky D.S. Chronic mild stress-induced anhedonia: greater effect in a genetic rat model of depression. Physiol. Behav. 1993, 54:1215-1220.
52. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32:281-294.
53. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., Krystal J.H., Mason G.F. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 2004, 61:705-713.
54. Sankar R., Mazarati A. Neurobiology of depression as a comorbidity of epilepsy. Epilepsia 2010, 51:81.
55. Sarkisova K.Y., Midzianovskaia I.S., Kulikov M.A. Depressive-like behavioral alterations and c-fos expression in the dopaminergic brain regions in WAG/Rij rats with genetic absence epilepsy. Behav. Brain Res. 2003, 144:211-226.
56. Seidenberg M., Kelly K.G., Parrish J., Geary E., Dow C., Rutecki P., Hermann B. Ipsilateral and contralateral MRI volumetric abnormalities in chronic unilateral temporal lobe epilepsy and their clinical correlates. Epilepsia 2005, 46:420-430.
57. Szakacs R., Janka Z., Kalman J. The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression. Neuropsychopharmacol. Hung. 2012, 14:29-40.
58. Toro C.T., Hallak J.E., Dunham J.S., Leite J.P., Sakamoto A.C., Guarnieri R., Fong V., Deakin J.F. The NR1 N-methyl-d-aspartate subunit and brain-derived neurotrophic factor in temporal lobe epilepsy hippocampus: a comparison of patients with and without coexisting psychiatric symptoms. Epilepsia 2007, 48:2352-2356.
59. Watson C., Paxions G. The Rat Brain in Stereotaxic Coordinates 2005, Elsevier Academic Press. 5th ed.
60. Waxman E.A., Lynch D.R. N-methyl-d-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005, 11:37-49.